Modalis was featured as one of the few epigenome editing therapeutics companies challenging CNS diseases (central nerve system diseases), which are difficult to develop therapeutics for with other modalities and have high unmet medical needs.

An interview article with Dr. Seth Levy, Senior Director Manufacturing, was published in Outsource Pharma

Our MDL-207 approach to Dravet Syndrome was featured in BioCentury.

Modalis Reports 2024 Financial Results and Operational Highlights

Modalis Therapeutics Reports Operational Highlights and Third Quarter 2024 Financial Results